Phaseline

Companies › Aspeya

Aspeya: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology, Respiratory; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASY202
Dihydroergotamine (DHE) inhalation powder - ergot alkaloid vasoconstrictive agent
–Phase 2Migraine; Safety in Asthma PatientsMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07646613ASY202Phase 2MigraineNeurologyMar 2027
NCT07665892ASY202Phase 1Safety in Asthma PatientsRespiratoryMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biossil Vicore Pharma SpliSense Sundance Biosciences Teikoku Pharma USA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.